OT-1096: Lead candidate in TNBC

OT-1096 is a next-generation small molecule immunomodulator targeting advanced metastasized triple-negative breast cancer (TNBC). Preclinical studies have shown positive efficacy and mechanism of action (MOA) has been proven. While TNBC is targeted first given today’s huge lack of effective treatment options, the aim is to be able to extend into other cancer forms in future.

About triple-negative breast cancer (TNBC)

Triple-negative breast cancer (TNBC) is a subgroup of the second most common cancer in women. The aggressive disease is characterized by the lack of over-expression of the human epidermal growth factor 2 (HER2) in addition to the absence of progesterone and estrogen receptors. With the cancer not depending on these hormones to support tumor growth, the disease type stands resilient towards the hormonal cancer treatment and is unlikely to respond to the standard of care therapies. TNBC has proved highly inclined to recur while also remaining highly diverse, heterogeneous, which has limited the development of targeted therapies. This leaves the patients with few efficacious options, e.g. only combinational cytotoxic treatments. In general, the prognosis of TNBC is very poor and the median metastatic survival is less than 12 months.1

Market potential

It is estimated that more than two million patients were affected by breast cancer under 2018, for which around 10-20% historically would test negative for both hormone receptors and the HER2 over-expressions.2 The market to address these 200 000 – 400 000 patients in dire need of new treatments is expected to grow due the introduction of premium priced therapeutics specifically targeted towards the disease and the launch of immunotherapies. Extrapolating* treatment ratios, pricing structures and rates of diagnosis for projections of market growth in the seven major markets the U.S., EU5 (Germany, France, Italy, Spain, UK) and Japan: the annual worldwide market for TNBC ranges between 1-2 billion USD in 2018, and is expected grow to the range between 3-6 billion USD by 2024.3

* Incidence cases of TNBC are expected to be treated only the initial 12 months.

1. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA (2015) Subtyping of triple-negative breast cancer: implications for therapy. Cancer, 121(1), 8–16 Link 2. The International Agency for Research on Cancer (IARC), 2018 Update on Globocan. Link 3. DataMonitor Healthcare Report – TNBC, Treatment, Epidemiology and Market forecast 2018.